Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function
Copyright © 2017 by the American Society of Nephrology..
BACKGROUND AND OBJECTIVES: Despite the high burden of CKD, few specific therapies are available that can halt disease progression. In animal models, clopidogrel has emerged as a potential therapy to preserve kidney function. The effect of clopidogrel on kidney function in humans has not been established.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Secondary Prevention of Small Subcortical Strokes Study randomized participants with prior lacunar stroke to treatment with aspirin or aspirin plus clopidogrel. We compared annual eGFR decline and incidence of rapid eGFR decline (≥30% from baseline) using generalized estimating equations and interval-censored proportional hazards regression, respectively. We also stratified our analyses by baseline eGFR, systolic BP target, and time after randomization.
RESULTS: At randomization, median age was 62 (interquartile range, 55-71) years old; 36% had a history of diabetes, 90% had hypertension, and the median eGFR was 81 (interquartile range, 65-94) ml/min per 1 m2. Persons receiving aspirin plus clopidogrel had an average annual change in kidney function of -1.39 (95% confidence interval, -1.15 to -1.62) ml/min per 1.73 m2 per year compared with -1.52 (95% confidence interval, -1.30 to -1.74) ml/min per 1.73 m2 per year among persons receiving aspirin only (P=0.42). Rapid kidney function decline occurred in 21% of participants receiving clopidogrel plus aspirin compared with 22% of participants receiving aspirin plus placebo (hazard ratio, 0.94; 95% confidence interval, 0.79 to 1.10; P=0.42). Findings did not vary by baseline eGFR, time after randomization, or systolic BP target (all P values for interaction were >0.3).
CONCLUSIONS: We found no effect of clopidogrel added to aspirin compared with aspirin alone on kidney function decline among persons with prior lacunar stroke.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical journal of the American Society of Nephrology : CJASN - 12(2017), 7 vom: 07. Juli, Seite 1040-1047 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ikeme, Jesse C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.04.2018 Date Revised 13.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2215/CJN.00100117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271326743 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271326743 | ||
| 003 | DE-627 | ||
| 005 | 20231224232452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2215/CJN.00100117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0904.xml |
| 035 | |a (DE-627)NLM271326743 | ||
| 035 | |a (NLM)28446537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ikeme, Jesse C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2018 | ||
| 500 | |a Date Revised 13.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: Despite the high burden of CKD, few specific therapies are available that can halt disease progression. In animal models, clopidogrel has emerged as a potential therapy to preserve kidney function. The effect of clopidogrel on kidney function in humans has not been established | ||
| 520 | |a DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Secondary Prevention of Small Subcortical Strokes Study randomized participants with prior lacunar stroke to treatment with aspirin or aspirin plus clopidogrel. We compared annual eGFR decline and incidence of rapid eGFR decline (≥30% from baseline) using generalized estimating equations and interval-censored proportional hazards regression, respectively. We also stratified our analyses by baseline eGFR, systolic BP target, and time after randomization | ||
| 520 | |a RESULTS: At randomization, median age was 62 (interquartile range, 55-71) years old; 36% had a history of diabetes, 90% had hypertension, and the median eGFR was 81 (interquartile range, 65-94) ml/min per 1 m2. Persons receiving aspirin plus clopidogrel had an average annual change in kidney function of -1.39 (95% confidence interval, -1.15 to -1.62) ml/min per 1.73 m2 per year compared with -1.52 (95% confidence interval, -1.30 to -1.74) ml/min per 1.73 m2 per year among persons receiving aspirin only (P=0.42). Rapid kidney function decline occurred in 21% of participants receiving clopidogrel plus aspirin compared with 22% of participants receiving aspirin plus placebo (hazard ratio, 0.94; 95% confidence interval, 0.79 to 1.10; P=0.42). Findings did not vary by baseline eGFR, time after randomization, or systolic BP target (all P values for interaction were >0.3) | ||
| 520 | |a CONCLUSIONS: We found no effect of clopidogrel added to aspirin compared with aspirin alone on kidney function decline among persons with prior lacunar stroke | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Confidence Intervals | |
| 650 | 4 | |a Disease Progression | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Models, Animal | |
| 650 | 4 | |a Random Allocation | |
| 650 | 4 | |a Renal Insufficiency, Chronic | |
| 650 | 4 | |a Secondary Prevention | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a Stroke, Lacunar | |
| 650 | 4 | |a Ticlopidine | |
| 650 | 4 | |a antiplatelet | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a clopidogrel | |
| 650 | 4 | |a creatinine | |
| 650 | 4 | |a decline | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a eGFR | |
| 650 | 4 | |a glomerular filtration rate | |
| 650 | 4 | |a hypertension | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Clopidogrel |2 NLM | |
| 650 | 7 | |a A74586SNO7 |2 NLM | |
| 650 | 7 | |a Ticlopidine |2 NLM | |
| 650 | 7 | |a OM90ZUW7M1 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Pergola, Pablo E |e verfasserin |4 aut | |
| 700 | 1 | |a Scherzer, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Shlipak, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Benavente, Oscar R |e verfasserin |4 aut | |
| 700 | 1 | |a Peralta, Carmen A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of the American Society of Nephrology : CJASN |d 2006 |g 12(2017), 7 vom: 07. Juli, Seite 1040-1047 |w (DE-627)NLM172123720 |x 1555-905X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:7 |g day:07 |g month:07 |g pages:1040-1047 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2215/CJN.00100117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 7 |b 07 |c 07 |h 1040-1047 | ||